Catalyst Pharmaceuticals (CPRX) 2025 Conference May 14, 2025 11:00 AM ET Speaker0 Here with our next company presenter at the BofA Annual Healthcare Conference. I'm pleased to be introducing our next company presenter Catalyst Pharmaceuticals and Richard Ailey, President and Chief Executive Officer and Steve Miller, COO and CSO. My name is Jason Gerberry. I cover SpitCat Biotech and Specialty Pharma at BofA. And so Catalyst, a commercial stage rare orphan focused company in growth mode and has a sort of a l ...

Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for the first quarter of 2025, beating the Zacks Consensus Estimate of 53 cents. The company had recorded adjusted earnings of 38 cents in the year-ago quarter.Total revenues, the majority of which comprised product revenues, amounted to $141.4 million in the reported quarter, representing growth of 44% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $130 million.Catalyst Pharmaceuticals’ top ...

Catalyst Pharmaceuticals (CPRX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Michael Kalb - Executive VP & CFORichard Daly - President & CEOJeff Del Carmen - Executive Vice President, Chief Commercial OfficerBenjamin Paluch - Equity Research Senior Associate - BiotechCharles Duncan - Managing DirectorRohan Mathur - Biopharma Equity Research AssociateGary Ingenito - Chief Medical & Regulatory OfficerFelix Ampomah - Senior Associate Conference Call Participants Asim Rana - Equity Analys ...

Catalyst Pharmaceuticals (CPRX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good day, everyone, and welcome to today's Catalyst Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. Later, you will have an Please note this call is being It is now my pleasure to turn today's program over to Mike Kalb, CFO. Please begin. Speaker1 Good morning, everyone, and thank you for joining our conference call to discuss C ...

Catalyst Pharmaceutical (CPRX) reported $141.42 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 43.6%. EPS of $0.68 for the same period compares to $0.38 a year ago.The reported revenue represents a surprise of +8.92% over the Zacks Consensus Estimate of $129.84 million. With the consensus EPS estimate being $0.53, the EPS surprise was +28.30%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectatio ...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28.30%. A quarter ago, it was expected that this specialty drug company would post earnings of $0.52 per share when it actually produced earnings of $0.70, delivering a surprise of 34.62%.Over the last four ...

Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be He ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | 76-0837053 | | --- | --- | | (State or other jur ...

Core Points - Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel medicines for patients with rare diseases [1][3] - The company will participate in the BofA Securities Health Care Conference 2025 on May 14, 2025, in Las Vegas, Nevada [1][2] - Catalyst has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies [3] Presentation Details - The presentation will take place on May 14, 2025, at 8:00 am PT [2] - A webcast of the presentation will be available on the company's website, with a replay accessible for at least 14 days [2] Company Overview - Catalyst Pharmaceuticals is committed to improving the lives of patients with rare diseases through innovative therapies and a comprehensive suite of support services [3] - The company maintains a strong U.S. presence and is actively seeking to expand its global commercial footprint through strategic partnerships [3]

Core Viewpoint - Catalyst Pharmaceuticals, Inc. will release its first quarter 2025 financial results on May 7, 2025, and will host a conference call and webcast on May 8, 2025, to discuss these results and provide a business update [1][2]. Company Overview - Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients with rare and difficult-to-treat diseases [4]. - The company has a proven track record of bringing life-changing treatments to market and prioritizes patient care through a comprehensive suite of support services [4]. - Catalyst is headquartered in Coral Gables, Florida, and has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies [4]. Conference Call & Webcast Details - The conference call and webcast will take place on May 8, 2025, at 8:30 AM ET [3]. - US/Canada dial-in number is (833) 316-2483, and the international dial-in number is (785) 838-9284 [3]. - The webcast will be accessible on the company's website, with a replay available for at least 30 days following the event [3].